# PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

> **NCT03655236** · PHASE2 · TERMINATED · sponsor: **Sun Pharma Advanced Research Company Limited** · enrollment: 513 (actual)

## Conditions studied

- Early Parkinson Disease

## Interventions

- **DRUG:** K0706
- **DRUG:** K0706
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT03655236
- **Lead sponsor:** Sun Pharma Advanced Research Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-18
- **Primary completion:** 2024-04-08
- **Final completion:** 2024-06-06
- **Target enrollment:** 513 (ACTUAL)
- **Why stopped:** Terminated based on study outcomes
- **Last updated:** 2025-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03655236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03655236, "PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03655236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*